Intensity Therapeutics Inc(INTS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -4.83 | Insider Own | 4.73% | Shs Outstand | 3.3M | Perf Week | 1% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 35.16% | Insider Trans | - | Shs Float | 3.1M | Perf Month | -3.81% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | -0.99 | Inst Own | 20.59% | Short Float | 2.63% | Perf Quarter | 8.02% |
| Income | -0.01B | P/S | - | EPS this Y | 59.46% | Inst Trans | 22.1% | Short Ratio | 1.95 | Perf Half Y | -48.93% |
| Sales | 0.00B | P/B | 1.29 | EPS next 5Y | 29.36% | ROA | -139.85% | Short Interest | 0.08M | Perf YTD | -60.6% |
| Book/sh | 3.13 | P/C | 1.38 | EPS past 3/5Y | 16.06% 5.76% | ROE | -195.88% | 52W High | -90.71% ($43.50) | Perf Year | -36.9% |
| Cash/sh | 2.92 | P/FCF | - | Sales past 3/5Y | - | ROIC | -120.34% | 52W Low | 15.1% ($3.51) | Perf 3Y | -96.79% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 76.63% | Gross Margin | - | Volatility(W/M) | 2.93% 6.69% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.24 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5 | EPS Q/Q | 66.95% | Profit Margin | - | RSI (14) | 42.18 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5 | Sales Q/Q | - | SMA20 | -5.48% ($4.27) | Beta | 3.02 | Target Price | $17.2 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/11 | SMA50 | -8.08% ($4.4) | Rel Volume | 0.06 | Prev Close | $4.02 |
| Employees | 16 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -27.22% - | SMA200 | -37.89% ($6.5) | Avg Volume(3M) | 0.04M | Price | $4.04 |
| IPO | 2023/6/30 | Option/Short | No/Yes | Trades | 111 | Volume | 2,338 | Change | 0.5% |
Company
INTS is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💉 This clinical-stage biotech develops INT230-6, a candidate cancer therapy based on a proprietary technology that is injected directly into solid tumors to kill cancer cells while also triggering an immune response. It is a U.S.-listed small-cap company currently running two trials simultaneously: the Phase 3 "INVINCIBLE-3" study in soft tissue sarcoma and the Phase 2 "INVINCIBLE-4" study in triple-negative breast cancer.
Over the past 1 year, on the lower side
91% below its 1-year high.
INTS has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +59.5% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -96.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 20.6%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
VXF 0.00%It ranks #4 in the industry
Based on market cap of $13M.
INTS $13M PER -
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is INTS?
INTS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of INTS?
The market cap of INTS is approximately $13M, ranking 5,434 within its sector.
What is the 52-week high and low for INTS?
INTS has recorded a 52-week high of $43.50 and a low of $3.51.
